Regulatory Storm for Jagsonpal Pharmaceuticals: Customs Order and FDA Warning Letter

Jagsonpal Pharmaceuticals Limited has been issued a customs order confirming a differential duty of ₹51 million plus a penalty. This development follows recent regulatory challenges faced by the company, including a warning letter from the U.S. FDA regarding significant manufacturing lapses at its Rajasthan-based facility.

 

Key Highlights:

This situation highlights the importance of regulatory compliance for pharmaceutical companies operating globally, as non-compliance can lead to significant financial and reputational consequences.

 

Sources: Jagsonpal Pharmaceuticals, U.S. FDA, Customs Authority